Cyclophosphamide and doxorubicin for recurrent ovarian cacner – pro
The CA regimen was rep[orted to have activity for ovarian cancer. The GOG (Gynecologic Oncology Group) trial comparing cyclophosphamide, melphalan and doxorubicin demonstrated an improvement in response rate; however, there was no OS advantage. Clinical trials studying the effect of this combination have shown a CR of 26% and median OS of 15.7 months with side effects such as nausea, vomiting, and leukocyte toxicity. However, there is a need for phase III testing of just the requested two drugs, the studies are old, NCCN does not list it, and many other recommended NCCN options are available.
Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CM, Tobias JS, Weiner RS, Frei E 3rd. Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15;46(4):669-74.
Ruchika Pokhriyal1, Roopa Hariprasad2, Lalit Kumar3 and Gururao Hariprasad, Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomarkers in Cancer Volume 11: 119 2019
Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a gynecologic oncology group study. Cancer. 1986;57:17251730.